ChemotherapyPhase 3 trialInvestigational
S-1
Generic name: tegafur + gimeracil + oteracil
How it works
S-1 is a combination of three chemotherapy drugs: tegafur, gimeracil, and oteracil. These drugs work together to interfere with DNA synthesis and cell division, causing cancer cells to die.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that S-1 can improve overall survival in patients with pancreatic cancer, with a median survival of approximately 8.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.